Hims & Hers enters its third-quarter report having already won the argument about demand. The harder question now is what that growth costs. Last quarter, the company's March pivot in weight loss produced a sharp revenue re-acceleration, a third straight increase to its full-year sales outlook and its largest acquisition ever. It also brought a six-point drop in adjusted gross margin, a lower ceiling on adjusted EBITDA, negative free cash flow and a fresh FTC lawsuit. This report is the first full test of whether the trade-off is paying off.

Wall Street expects revenue of about $893.4 million, which would mean growth of roughly 49% from the $599 million reported a year ago. That figure sits near the top of management's $880 million to $900 million guidance range, so analysts are effectively assuming the company delivers on its own plan with little cushion. Consensus calls for earnings of $0.07 a share, up from $0.06 a year earlier, while the Earnings Whisper of $0.09 suggests some investors expect a modest upside surprise. The gap is small in dollars but notable for a company that posted a loss of $0.10 last quarter on about $81 million of one-time acquisition, restructuring and legal costs. A clean quarter without those charges matters as much as the headline number.

The contrast between the revenue and earnings growth rates tells the story. Sales are expected to rise nearly 50%, while per-share profit is projected to grow far more slowly, reflecting a mix shift toward branded weight-loss products and international markets that carry thinner margins. Management has told investors to expect gross margin to stay well below its historical low-70s level, so another decline from the 64% posted last quarter would not by itself be alarming. What would challenge the narrative is margin erosion that outpaces the operating leverage management promised. The company has pointed to an EBITDA margin climbing toward roughly 12% by the fourth quarter, so a third-quarter figure that stalls near last quarter's 8% would raise doubts about the trimmed $275 million to $325 million full-year EBITDA outlook.

Cash flow may be the most revealing line. Working capital tied to branded weight loss drove free cash flow to negative $68 million last quarter and pushed the company to add a $400 million receivables facility and more than $400 million in convertible debt. Evidence that cash burn is easing would validate the view that the strain was a ramp-up effect rather than a permanent feature of the new model. Beyond that, the catalysts management highlighted deserve scrutiny: whether Eucalyptus keeps international revenue on track for at least $600 million this year, whether testosterone crosses into its sixth $100 million U.S. specialty, and whether the AI-driven Hers weight-loss experience is translating into lower cancellations and support costs. Any update on the contested FTC complaint will also be closely parsed.

The market has not given the company much credit for its growth. Shares have fallen about 6.8% since the last report, trailing the S&P 500 by more than four percentage points, and at $27.68 the stock sits near the bottom of its post-earnings range of $26.33 to $34.46, barely above its 200-day moving average. Sentiment remains bearish, though slightly less so than a quarter ago. That combination suggests skepticism is focused on profitability and risk rather than on the top line.

With the revenue bar set near the high end of guidance and the full-year outlook already raised three times, simply hitting sales targets may not be enough. The narrative stays intact if Hims & Hers can show that its surge in weight-loss and international revenue is beginning to convert into improving EBITDA and steadier cash generation. Another strong top line paired with deeper margin pressure and continued cash burn would leave investors wondering whether the company is buying growth rather than earning it.